Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest blood clots Stories

2012-05-02 10:26:21

CRESSKILL, N.J., May 2, 2012 /PRNewswire/ -- Deadlines for lawsuits over side effects of the birth control drugs Yaz and Yasmin have been moved back another 90 days, the third time deadlines have been delayed this year. The extension by Chief Judge David R. Herndon, of the U.S. District Court for the Southern District of Illinois, allows settlement negotiations to continue between Bayer and lawyers for the more than 11,500 lawsuits that have been lodged against the drugs' manufacturer, Bayer....

2012-05-02 02:28:13

RARITAN, N.J., May 2, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, (Janssen), announced today that it has submitted supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to treat patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent venous thromboembolism (VTE). These submissions are supported by data from the...

New Birth Control Labels Detail Increased Risk For Blood Clots
2012-04-11 12:37:21

The US Food and Drug Administration (FDA) has begun to add information to labels of popular birth control medications to warn about the increased risk of blood clots. Bayer AG´s “Yaz” or Yasmin is one of the medications receiving the new label, though all common types of birth control pills increase a woman´s risk of potentially fatal blood clots. The FDA is following up new studies with these labels, saying certain forms of birth control like Yaz show an even...

2012-03-28 00:35:25

Study finds new treatment approach could benefit hundreds of thousands per year Pulmonary embolism -- the sudden blockage of an artery in the lung -- is estimated to cause over 100,000 deaths each year in the U.S. Although thrombolytics, or "clot-buster" drugs, are currently reserved to treat only the most severe cases of pulmonary embolism, new data suggest that when used at lower doses, these drugs are also safe and effective for more common, moderate cases of pulmonary embolism,...

2012-03-26 02:26:29

CHICAGO, March 26, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, (Janssen), announced results of the EINSTEIN-PE study showing that the oral anticoagulant XARELTO(®) (rivaroxaban) was comparable to today's standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary venous blood clot (known as venous thromboembolism or VTE). The study also found rivaroxaban had a similar safety profile and significantly...

2012-02-27 15:30:00

RARITAN, N.J., Feb. 27, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (JRD) announced today that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS). The FDA grants Priority Review to medicines that offer...

2012-02-14 11:40:16

The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood clots, use of LMWH is low compared to...

2012-02-14 08:00:00

DENVER, Feb. 14, 2012 /PRNewswire/ -- The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood...

2012-02-03 19:00:24

An experimental device for removing blood clots in stroke patients dramatically outperformed the standard mechanical treatment, according to research presented by UCLA Stroke Center director Dr. Jeffrey L. Saver at the American Stroke Association's 2012 international conference in New Orleans on Feb. 3. The SOLITAIRE Flow Restoration Device is among an entirely new generation of devices designed to remove blood clots from blocked brain arteries in patients experiencing stroke. It has a...

2012-01-02 20:00:00

Women Who Suffered Blood Clots After Using Yaz, Yasmin or Ocella Birth Control Pills May be Entitled to File Lawsuits to Recover Damages for Their Injuries Naples, FL (PRWEB) January 02, 2012 Recent research has indicated that young women who use Yaz, Yasmin, Ocella or other birth control pills containing the progestin, drospirenone, may face a higher risk of blood clots compared to those taking other oral contraceptives. Gilman Law LLP is actively investigating potential lawsuits on behalf...